<DOC>
	<DOCNO>NCT00389207</DOCNO>
	<brief_summary>Primary purpose study compare efficacy safety two different nevirapine ( Viramune ) dose regimen ( daily ( QD ) twice daily ( BID ) application ) atazanavir/ritonavir ( Reyataz/Norvir ) , emtricitabine/tenofovir disoproxil fumarate ( DF ) ( Truvada ) background . Patients receive either nevirapine ( NVP ) 200 mg twice daily , NVP 400 mg daily , ritonavir-boosted atazanavir ( ATZ/r ) , combination emtricitabine ( FTC ) tenofovir DF ( TDF ) . All patient receive NVP start 200 mg daily 2 week , demonstrate lead-in dose regimen reduces frequency NVP-induced rash . At Visit 3 ( Week 2 ) , patient increase NVP dose either 200 mg twice daily 400 mg daily . Patients receive ATZ/r treat ATZ 300 mg daily , boost 100 mg ritonavir ( RTV ) daily . Background antiretroviral therapy patient consist one tablet Truvada . Treatment duration 48 week ( primary endpoint ) extension 144 week . Patients may also participate metabolic sub-study , compare NVP ATZ/r sign symptom lipodystrophy serum lipid/glycaemic abnormality .</brief_summary>
	<brief_title>Nevirapine Atazanavir/Ritonavir Given With Emtricitabine/Tenofovir Human Immunodeficiency Virus ( HIV ) -1-infected Treatment Naive Adults</brief_title>
	<detailed_description />
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
	<mesh_term>Ritonavir</mesh_term>
	<mesh_term>Atazanavir Sulfate</mesh_term>
	<mesh_term>Nevirapine</mesh_term>
	<mesh_term>Emtricitabine</mesh_term>
	<mesh_term>Tenofovir</mesh_term>
	<criteria>Inclusion criterion : 1 . Signed informed consent accordance Good Clinical Practice ( GCP ) local regulatory requirement prior trial participation 2 . HIV1infected male female &gt; = 18 year age positive serology confirm Western blot 3 . No previous antiretroviral treatment ( 7 day ) 4 . Males CD4+ count &lt; 400 cells/mm3 female CD4+ count &lt; 250 cells/mm3 5 . NVP ATZ/r susceptibility base HIV1 genotypic resistance report 6 . Adequate renal function define calculated creatinine clearance ( CLCr ) &gt; = 50 ml/min accord CockcroftGault formula 7 . Karnofsky score &gt; = 70 8 . Acceptable medical history , assess investigator Exclusion criterion : 1 . Active drug abuse chronic alcoholism investigator 's discretion 2 . Hepatic cirrhosis stage ChildPugh B C 3 . Female patient childbearing potential : positive serum pregnancy test screening study , breast feeding , plan become pregnant , willing use barrier method contraception , willing use method contraception ethinyl estradiol contain oral contraceptive 4 . Laboratory parameter Division Acquired Immunodeficiency Syndrome ( DAIDS ) &gt; grade 2 ( triglyceride &gt; DAIDS grade 3 ; total cholesterol restriction ) 5 . Active hepatitis B C disease , define HBsAgpositive Hepatitis CVirusRibo Nucleic Acid ( HCVRNA ) positive Aspartate Transaminase/Alanine Transaminase ( AST/ALT ) &gt; 2.5x Upper Limit Normal ( ULN ) ( DAIDS grade 1 ) 6 . Hypersensitivity ingredient test product 7 . Have therapy nephrotoxic drug ( e.g. , aminoglycosides , amphotericin B , vancomycin , cidofovir , foscarnet , cisplatin , pentamidine , tacrolimus , cyclosporine ) potential competitor renal excretion ( e.g. , cidofovir , acyclovir , valacyclovir , ganciclovir , valganciclovir , probenecid , highdose nonsteroidal antiinflammatory drug ( i.e. , ibuprofen ) ) within 3 month prior study screen expect receive study 8 . Patients receive concomitant treatment permit 9 . Use investigational medication within 30 day study entry trial 10 . Use immunomodulatory drug within 30 day study entry trial ( e.g. , interferon , cyclosporin , hydroxyurea , interleukin 2 , chronic treatment prednisone ) 11 . Patients Progressive Multifocal Leukoencephalopathy ( PML ) , Visceral Kaposi 's Sarcoma ( KS ) , and/or lymphoma 12 . Any AIDS defining illness unresolved , symptomatic stable treatment least 12 week screen visit 13 . Patients receive systemic treatment malignant disease</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2013</verification_date>
</DOC>